| Clinical data | |
|---|---|
| Other names | Mycobacterium obuense (heat-killed) |
| Identifiers | |
| UNII | |
IMM-101 is an immunomodulatory drug that is being studied to see if it is useful in chemotherapy. It consists of heat-killed Mycobacterium obuense bacteria. It may have relatively few side effects compared to other drugs.
References
- Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, et al. (September 2016). "Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer". British Journal of Cancer. 115 (7): 789–796. doi:10.1038/bjc.2016.271. PMC 5046215. PMID 27599039.
- Boseley S (6 September 2016). "New drug 'wakes up' immune system to fight one of deadliest cancers". The Guardian.
- Dalgleish V (17 March 2015). "A trial looking at a new type of immunotherapy for cancer of the pancreas that can't be removed with surgery". Cancer Research UK.
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |